NCT04657068 – A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors

This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to:

• Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan
• Learn more about the side effects of ART0380 alone and in combination with gemcitabine or irinotecan
• Learn more about the effectiveness of ART0380 alone and in combination with gemcitabine or irinotecan

Learn More